Chronic Intestinal Pathologies Analytical Cohort at TouLouse

Study Overview
=================
Brief Summary
-----------------
In the general population, the percentage of people with at least one digestive disease is 16.7%. Among these digestive diseases, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and patients who should benefit from digestive examinations as part of a screening oriented either by the patient's family history or following the performance of an immunological screening test ( FIT) in the stool will be studied. The aim of this project is to build a biological collection with associated clinical data for research projects.

Detailed Description
-----------------
In the general population, the percentage of people with at least one digestive disease is 16.7%. Among these digestive diseases, two of them namely inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) will be more particularly studied. This interest is based on the increasing frequency of these two pathologies, their chronicities but above all the limited physiopathological data available. In addition, it seems interesting to study a third population, namely patients who should benefit from digestive examinations as part of a screening oriented either by the patient's family history or following the performance of an immunological screening test ( FIT) in the stool. The study of this population is part of an improvement in knowledge on the carcinogenesis of colorectal cancer. To study these populations, blood, serum, plasma and tissues from colonous biopsies or surgical samples will be collected. This cohort will make it possible to study, among other things, the pathophysiology of chronic diseases of the small intestine and the colon (IBD, IBS, screening) in order to improve their management through the development of new biomarkers and therapeutic targets.

Official Title
-----------------
Chronic Intestinal Pathologies Analytical Cohort at TouLouse

Conditions
-----------------
Inflammatory Bowel Diseases, Colon Cancer

Intervention / Treatment
-----------------
* Biological: blood and intestinal biopsy sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient requiring endoscopic explorations for screening or follow-up in the context of a suspected IBS or IBD or colorectal cancer Or Patient with IBD requiring surgical management Patient over 18 years old Patient able to read and understand the information leaflet Patients who have given their consent to participate in the study Patients affiliated to a social security system (including AME) Exclusion Criteria: Patients who have received antibiotic treatments in the 10 days preceding endoscopic exploration Pregnant or breastfeeding patients Patients under 18 years old Patients under guardianship or curatorship Patients unable to sign a free and informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patient screened or followed-up for IBS or IBD or colorectal cancer<br>Blood and colon biopsy sampling | Biological: blood and intestinal biopsy sampling<br>* 24 mL of blood and 10 intestinal biopsies will be sampled<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biological collection associated with clinical data | Set up a biological collection associated with clinical data on main intestinal tract diseases in order to understand their physiopathology | Baseline | 
| Biological collection associated with clinical data | Set up a biological collection associated with clinical data on main intestinal tract diseases in order to understand their physiopathology | pre-intervention/procedure/surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identify new potential therapeutic molecules | Assessment of new treatment on organoids made thanks to intestinal biopsies | Baseline | 
| Optimize treatment success rates for IBD | Assessment of new treatment on organoids made thanks to intestinal biopsies | Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Intestinal Bowel syndrome, Inflammatory Bowel Disease, colon cancer screening, data and biological collection